TWINLAB CONSOLIDATED HOLDINGS, INC.
CIK 1590695fmd_0EG23TM6XGWZQZ7SS6ZD69KGH4Manufacturing · Medicinal Chemicals & Botanical ProductsTemplate: Standard
Coverage: Jan 01, 2013 to Dec 31, 2024, 49 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 86 | 73 | 73 | 66 | 72 | 17 | 14 | 12 |
| Cost of revenue | 70 | 65 | 66 | 60 | 62 | 55 | 56 | 9 | 9 | 8 |
| Gross profit | 12 | 21 | 19 | 13 | 11 | 11 | 17 | 8 | 5 | 4 |
| Research and development | 2 | 1 | 1 | 0 | 0 | 0 | – | – | – | – |
| Selling, general and administrative | 26 | 33 | 29 | 27 | – | – | – | – | – | – |
| Total operating expenses | – | – | 40 | 27 | – | – | – | – | – | – |
| Operating income | (14) | (12) | (21) | (14) | (39) | (5) | (8) | (2) | (1) | (2) |
| Interest expense | 7 | 9 | 9 | 10 | 10 | 9 | 9 | 8 | 8 | 8 |
| Other non-operating income (expense) | (22) | 13 | (9) | (6) | (6) | (9) | (7) | (6) | (8) | (8) |
| Income before taxes | (36) | 0 | (30) | (20) | (44) | (14) | (15) | (8) | (10) | (10) |
| Income tax expense | 0 | 1 | (1) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (36) | (1) | (29) | (20) | (45) | (14) | (15) | (8) | (10) | (10) |
| Net income | (36) | (1) | (29) | (20) | (45) | (14) | (15) | (8) | (14) | (9) |
| Net income to common shareholders | (36) | (25) | (29) | (23) | (48) | (14) | (15) | – | – | – |